No black box warning on record for Avlayah

As of the latest FDA labeling reviewed, Avlayah (TIVIDENOFUSP ALFA-EKNM) does not carry a black box warning. Standard warnings and precautions still apply — see the full Avlayah medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Infusion-Associated Reactions (IARs) : If a severe IAR occurs, discontinue AVLAYAH and initiate appropriate medical treatment. ( 5.2 ) Anemia : Obtain baseline hemoglobin levels in all patients and monitor 3 months after initiation, and as clinically indicated. Administer appropriate supportive measures for anemia based on clinical judgment. ( 5.3 ) Membranous Nephropath

No black box warning on record for Avlayah

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Infusion-Associated Reactions (IARs) : If a severe IAR occurs, discontinue AVLAYAH and initiate appropriate medical treatment. ( 5.2 ) Anemia : Obtain baseline hemoglobin levels in all patients and monitor 3 months after initiation, and as clinically indicated. Administer appropriate supportive measures for anemia based on clinical judgment. ( 5.3 ) Membranous Nephropath

Avlayah Black Box Warning

No black box warning on record for Avlayah

Other warnings & precautions

Avlayah Black Box Warning

No black box warning on record for Avlayah

Other warnings & precautions